PG2 shots to reduce moderate to severe breast cancer fatigue
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests whether PG2 injections can safely reduce moderate to severe fatigue in people receiving chemotherapy for locally advanced, recurrent, or metastatic breast cancer. If you qualify, you may be asked to complete questionnaires and follow study plans for about 8 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 20 or older
- You are receiving chemotherapy through an IV infusion right now
- Your fatigue is moderate-to-severe (score 4 or higher) on at least two checks, at least 14 days apart
- Your pain is fairly controlled (pain score 0–10 must be 4 or less)
- Your blood tests are acceptable (hemoglobin at least 10, and kidney/liver tests within required limits)
- You can complete study questionnaires and have at least 3 months of expected life
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether pioglitazone can reduce fatigue in people with certain types of breast cancer. You may be eligible if your cancer is estrogen- and progesterone-positive (ER+/PR+) and you plan surgery soon.
This study tests whether a medication called megestrol acetate can help reduce severe tiredness and fatigue in people with advanced breast cancer who are receiving a targeted therapy called T-DXd (trastuzumab deruxtecan). Fatigue is a common side effect that can really impact quality of life.
This study compares two ways of giving a large-volume injection of Phesgo (a targeted breast cancer treatment) to see which one is less painful. Half of the injections use a special device with a steady speed; the other half are done by hand. You will receive both methods, and you'll rate your pain, helping find a more comfortable way to give the medicine.
This study tests a combination of treatments (including education and counseling) to see if they can reduce severe fatigue in people with advanced cancer. It's for patients who are seen at MD Anderson Cancer Center in Texas and can attend sessions in person or online.
This trial tests two hormone-blocking injections (leuprolide and goserelin) to suppress ovarian function in premenopausal women with breast cancer. It aims to see how well these drugs work when taken with standard hormone pills.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
Hear when a new Cancer-related Fatigue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.